Fig. 5From: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective studyThe PFS of patients treated with everolimus based on PIK3CA/H1047R mutations. A total of 16 patients underwent ctDNA analysis; 6 patients had PIK3CA/H1047R mutations (blue), and 10 patients did not have PIK3CA/H1047R mutations (red). PFS, progression-free survival. PIK3CA, phosphatidylinositol 3-kinaseBack to article page